Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Aasld

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Nov 17, 2020 1:03pm

111 Views

Post# 31915149

RE:RE:Aasld

At some point eventually big pharma will buy all the leading Nash drug you'd expect. And ultimately what matters is the ability of these drugs to impact not just surrogate endpoints but the long term endpoints like end stage liver diseases and CV events. Pharma bucks will be purchasing drugs on what they can show about those long term outcomes because that's what gives the drug a long life. Yes they need to get the Ph3 done but I hope they don't just restrict themselves to that, I hope they get creative and flesh out the bigger issues. I hope Grinspoon's brain is whirring and he can nudge them to what he thinks will be clinically valuable. It'll never happen but I'd love to have Grinspoon as (part-time) Chief Scientific Officer driving the research.

SPCEO1 wrote: I think I have mentioned it before but my uneducated view is that, in the end, Egrifta will be shown to be useful in many other ways than just helping with NASH and CV benefits are at the top of my list for additional benefits. We are a long way from knowing anything about that, however, but it just makes sense to me that this will be the case.

qwerty22 wrote: Thought this was a good summary of the highlights of aasld so sharing. Crazy how Loomba is at the center of so much.
https://www.hepmag.com/article/pipeline-nafld-nash-treatment

This one is super intriguing given tesamorelin's history. I don't expect it changes any paradigms but maybe it's something to think about when Ph4s roll around.
https://www.newswise.com/articles/high-abdominal-fat-and-low-liver-fat-combo-increases-coronary-heart-disease-risk
It is intriguing maybe given some of the secondary measurements THTX might make during the Ph3. It strikes me that mdgl see what their drug is capable of and then shift the discussion towards that. Thtx could think about doing something similar.